Plasma homocysteine and vascular disease in elderly patients with mental illness

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 11, 2008, Pages 1556-1561

  Nilsson, Karin ^a   Gustafson, Lars ^a   Hultberg, Björn ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Homocysteine; Mental illness; Vascular dementia; Vascular disease

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYSTATIN C; HOMOCYSTEINE;

AGED; AGING; ALZHEIMER DISEASE; BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DISEASE COURSE; GERIATRIC PATIENT; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MENTAL DISEASE; MULTIINFARCT DEMENTIA; PLASMA; PRIORITY JOURNAL; RISK FACTOR; SERUM; SHORT SURVEY; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DEMENTIA; HOMOCYSTEINE; HUMANS; MENTAL DISORDERS; RISK FACTORS; VASCULAR DISEASES;

EID: 56549111885     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.301     Document Type: Short Survey

References (69)

1. Nilsson K, Gustafson L, Fäldt R, Andersson A, Brattström L, Lindgren A, et al. Hyperhomocysteinemia - a common finding in a psychogeriatric population. Eur J Clin Invest 1996;26:853-9.
2. Joosten E, Lesaffre E, Riezler R, Ghekiere V, Dereymaeker L, Pelemans W, et al. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J Geront Med Sci 1997;52:M76-9.
3. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449-55.
4. McCaddon A, Davies G, Hudson P, Tandy S, Cattel H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Ger Psychiatry 1998;13:235-9.
5. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dementia 1999;10:12-20.
6. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype and risk for stroke, vascular dementia and Alzheimer disease in Northern Ireland. Stroke 2002;33:2351-6.
7. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M, et al. Homocysteine, folate and vitamin B-12 in mild cognitive impairment, Alzheimer's disease and vascular dementia. Am J Clin Nutr 2004;80:114-22.
8. Ravaglia G, Forti P, Maioli F, Muscari A, Sacchetti L, Arnone G, et al. Homocysteine and cognitive function in healthy elderly community dwellers in Italy. Am J Clin Nutr 2003;77:668-73.
9. Duthie SJ, Whalley LJ, Collins AR, Leaper S, Berger K, Deary I. Homocysteine, B-vitamin status, and cognitive function in the elderly. Am J Clin Nutr 2002;75:908-13.
10. Haan MN. Miller JW, Aiello AE, Whitmer RA, Jagust WJ, Mungas DM, et al. Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. Am J Clin Nutr 2007;85:511-7.
11. Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 2006;580:2994-3005.
12. Bottiglieri T. Folate, vitamin B-12 and neuropsychiatric disorders. Nutr Rev 1996;54:382-90.
13. Wagner C, Koury MJ. S-Adenosylhomocysteine - a better indicator of vascular disease than homocysteine. Am J Clin Nutr 2007;86:1581-5.
14. Ellison M, Thomas J, Patterson A. A critical evaluation of the relationship between serum vitamin B12, folate and total homocysteine with cognitive impairment in the elderly. J Hum Nutr Diet 2004;17:371-83.
15. Eussen SJ, de Groot LC, Joosten LW, Bloom RJ, Clarke R, Ueland PM, et al. Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr 2006;84:361-70.
16. Refsum H, Smith DA, Ueland PM, Nexö E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3-32.
17. Brattström L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994;236:633-41.
18. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine concentration and its relation to symptoms of vascular disease in psychogeriatric patients. Dement Geriatr Cogn Disord 2005;20:35-41.
19. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine and vascular disease in elderly patients with psychogeriatric disease. Dement Geriatr Cogn Disord 2006;21:148-54.
20. Ganji V, Kafai MR. Trends in serum folate, RBC folate and circulating total homocysteine concentrations in the United States: analysis of data from National Health and Nutrition Examination Surveys, 1988-1994, 1999-2000, and 2001-2002. J Nutr 2006;136:153-8.
21. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002;325:1202-9.
22. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a metaanalysis. J Am Med Assoc 2002;288:2015-22.
23. Wald DS, Morris JK, Law M, Wald NJ. Folic acid, homocysteine and cardiovascular disease: judging causality in the face of inconclusive trial evidence. Br Med J 2006;333:1114-7.
24. Herrmann W. Homocysteine research: alive and kicking! Clin Chem Lab Med 2007;45:1571-4.
25. Ueland PM, Clarke R. Homocysteine and cardiovascular risk: considering the evidence in the context of study design, folate fortification, and statistical power. Clin Chem 2007;53:807-9.
26. Castro R, Rivera I, Blom HJ, Jakobs C, Tavares de Almeida I. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J Inherit Metab Dis 2006;29:3-20.
27. Nilsson K, Gustafson L, Hultberg B. Relation between plasma homocysteine and Alzheimer's disease. Dement Geriatr Cogn Disord 2002;14:7-12.
28. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine, cobalamin/folate status, and vascular disease in a large population of psychogeriatric patients. Dement Geriatr Cogn Disord 2006:22:358-66.
29. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine is elevated in elderly patients with memory complaints and vascular disease. Dement Geriatr Cogn Disord 2007;23:321-6.
30. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. J Am Med Assoc 2004;291:565-75.
31. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. for the NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
32. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
33. Loscalzo J. Homocysteine trials - clear outcomes for complex reasons. N Engl J Med 2006;354:1629-32.
34. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 2006;354:2764-72.
35. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007;369:1876-82.
36. Nilsson K, Gustafson L, Hultberg B. Elevated plasma homocysteine concentration in elderly patients with mental illness is mainly related to the presence of vascular disease and not the diagnosis. Dement Geriatr Cogn Disord 2007;24:162-8.
37. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-83.
38. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Homocysteine and folate as risk factors for dementia and Alzheimer's disease. Am J Clin Nutr 2005;82:636-43.
39. Selhub J. The many facets of hyperhomocysteinemia: studies from the Framingham Cohorts. J Nutr 2006;136:1726S-30S.
40. Luchsinger JA, Tang M-X, Shea S, Miller J, Green R, Mayeaux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology 2004;62:1972-6.
41. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine concentration relates to the severity but not to the duration of Alzheimer's disease. Int J Ger Psychiatry 2004;19:666-72.
42. Mielke MM, Zandi PP. Hematologic risk factors of vascular disease and their relation to dementia. Dement Geriatr Cogn Disord 2006;21:335-52.
43. Brun A. The neuropathology of vascular dementia and its overlap with Alzheimer's disease. In: O'Brien J, Ames D, Gustafson L, Folstein M, Chiu E, editors. Cerebrovascular disease, cognitive impairment and dementia, 2nd ed. London: Martin Dunitz, Taylor & Francis Group, 2004:103-15.
44. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-5.
45. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu-Asia Aging Study. Neurobiol Aging 2000;21:49-55.
46. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, et al. Atherosclerosis apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151-4.
47. Ott A, Breteler MM, de Bruyne MC, van Harskamp FC, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997;28:316-21.
48. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and risk of dementia: the Rotterdam Study. Neurology 1999;53:1937-42.
49. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, et al. Stroke and the risk of Alzheimer's disease. Arch Neurol 2003;60:1707-12.
50. Rosendorff C, Beeri MS, Silverman JM. Cardiovascular risk factors for Alzheimer's disease. Am J Geriatr Cardiol 2007;16:143-9.
51. Kalaria R. Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci 2002;203:29-34.
52. Korczyn AD. The underdiagnosis of the vascular contribution to dementia. J Neurol Sci 2005;229-230:3-6.
53. Mielke MM, Rosenberg PB, Tschanz J, Cook L, Hayden KM, Norton M, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007;69:1850-8.
54. Song IU, Kim JS, Eah KY, Lee KS. Clinical significance of silent cerebral infarctions in patients with Alzheimer disease. Cogn Behav Neurol 2007;20:93-8.
55. Sheng B, Cheng LF, Law CB, Li HL, Yeung KM, Lau KK. Coexisting cerebral infarction in Alzheimer's disease is associated with fast dementia progression: applying the National Institute for Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Énseignement en Neurosciences Neuroimaging Criteria in Alzheimer's Disease with Concomitant Cerebral Infarction. J Am Geriatr Soc 2007;55:918-22.
56. Alagiakrishnan A, McCracen P, Feldman H. Treating vascular risk factors and maintaining vascular health: is this the way towards successful cognitive ageing and preventing cognitive decline? Postgrad Med J 2006;82:101-5.
57. Nilsson K, Gustafson L, Hultberg B. Homocysteine, cystatin C and N-terminal-pro brain natriuretic peptide. Vascular risk markers in elderly patients with mental illness. Dement Geriatr Cogn Disord 2007;25:88-96.
58. Struthers AD, Davies J. B-type natriuretic peptide: a simple new test to identify coronary artery disease? Q J Med 2005;98:765-9.
59. Bökenkamp A, Herget-Rosenthal S, Bökenkamp R. Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol 2006;21:1223-30.
60. Manjunath G, Tighiouart H, Coresh J, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003;63:1121-9.
61. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology and epidemiology and prevention. Circulation 2003;108:2154-69.
62. Galasko GI, Lahiri A, Barnes SC, Collison P, Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J 2005;26:2269-76.
63. Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal proBNP as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005;48:156-63.
64. Nilsson K, Gustafson L, Hultberg B. C-reactive protein - vascular risk marker in elderly patients with mental illness. Dement Geriatr Cogn Disord 2008. In press.
65. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347;1557-65.
66. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P. Low grade inflammation and coronary heart disease: prospective study and updated metaanalyses. Br Med J 2000;321:199-204.
67. Kuo HS, Yen CJ, Chang CH, Kuo CK Chen JH, Sorond F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 2005;4:371-80.
68. Pearson TA, Menash GA, Alexander RW, Anderson J, Cannen R, Criqui M. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
69. Qui C, De Ronchi D, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 2007;20:380-5.